knowledge -WSS

knowledge

author：comprehensive 2025-09-30 22:41:32 - browse：56

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Virtual Event: March of the Biosimilars

WSS

Stop the failed accountable care organization experiment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Asbestos, a deadly carcinogen, banned by EPA

Methadone treatment changes are coming. Do they go far enough?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Virtual Event: March of the Biosimilars

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Heart attack and stroke risk calculators need revising

After decades in use, heart stents finally beat placebo

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Duchenne breakthrough therapy leaves behind pioneering families

White House drug czar issues call for 'recovery

Malaria cases in Florida and Texas: Here’s what you need to know

Physicians and social media: If you see something, say something?

Supreme Court strikes down use of affirmative action

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

focus

Nurses recount patients attacks

What health policies could hitch a ride on a spending bill?

Leading voice in opioid treatment defends methadone clinic system

NIH chief: government has fallen behind pharma on clinical trials

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Methadone treatment changes are coming. Do they go far enough?

hotspot

entertainment

focus

Wikipedia